

Cheaper breast cancer therapy

Monday 23 January 2017

The drug trastuzumab (trade name Herceptin) can markedly prolong survival of around a quarter of women with breast cancer, but it's too costly for many to access.

It's a complex drug, made in living cells, and it wasn't known if a cheaper copy, known as a biosimilar, would work as well.

New research shows it does, paving the way for vastly more women to benefit.

Guests

Dr Hope S Rugo

Professor of Medicine and Director Breast Oncology, Comprehensive Cancer Centre, University of California San Francisco.

Further Information

[Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 \(HER2\)-positive metastatic breast cancer: a randomized clinical trial - JAMA \[S\]](#)

[Biosimilar therapy for ERBB2 \(HER2\)-positive breast cancer - close enough? JAMA \[S\]](#)

[Scientific evidence and financial obligations to ensure access to biosimilars for cancer treatment - JAMA \[S\]](#)